Dennis Joseph Slamon (born August 6, 1948), [1][2] is an American oncologist and chief of the division of Hematology-Oncology at UCLA. He is best known for his work identifying the HER2/neu oncogene that is amplified in 25-33% of breast cancer patients and the resulting treatment trastuzumab. Slamon, MD, PhD, serves as director of Clinical/Translational Research, and as director of the Revlon/UCLA Women's Cancer Research Program at JCCC. He is a professor of medicine, chief of the Division of Hematology/Oncology and executive vice chair for research for UCLA's Department of Medicine. Slamon also serves as director of the medical advisory board for the National Colorectal ... DennisSlamon In the early 1990s, women who were diagnosed with HER2-positive breast cancer weren't expected to live more than three to five years after diagnosis. That changed when a team of scientists led by Dr. DennisSlamon, chief of hematology/oncology at the David Geffen School of Medicine at UCLA, developed what became known as Herceptin. Slamon's journey from humble beginnings to revolutionizing cancertreatment through molecular medicine and industry collaborations is a story of passion, perseverance, and impact in the field of oncology. Slamon, M.D., Ph.D., a UCLA oncologist and researcher, transformed breast cancertreatment through his pioneering identification of the HER2/neu oncogene, amplified in roughly a quarter to a third of breast cancers. His seminal work revealed that this molecular marker signified aggressive disease but could be effectively targeted. This led directly to the development of ... A Conversation with Dr. DennisSlamon: The Breakthrough Behind Herceptin and the Future of Cancer Research In this special episode, Dr. Sujuan Ba, CEO of the National Foundation for Cancer ...
